Skip to main content
Erschienen in: Dermatology and Therapy 3/2023

Open Access 17.01.2023 | Original Research

Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study

verfasst von: Akihiko Asahina, Yukari Okubo, Akimichi Morita, Yayoi Tada, Atsuyuki Igarashi, Richard G. Langley, Delphine Deherder, Mizuho Matano, Veerle Vanvoorden, Maggie Wang, Mamitaro Ohtsuki, Hidemi Nakagawa

Erschienen in: Dermatology and Therapy | Ausgabe 3/2023

Abstract

Introduction

Bimekizumab treatment resulted in improved clinical outcomes in patients with moderate-to-severe plaque psoriasis in BE VIVID, a 52-week, phase 3, randomized, ustekinumab and placebo-controlled study. We present data from the BE VIVID Japan patient subpopulation.

Methods

Globally, patients were randomized to receive bimekizumab 320 mg every 4 weeks (Q4W), ustekinumab (45/90 mg weight-based at baseline and week 4, then every 12 weeks), or placebo (Q4W through week 16, then bimekizumab 320 mg Q4W). Efficacy endpoints included week 16 Psoriasis Area and Severity Index (PASI) 90 and Investigator’s Global Assessment (IGA) 0/1, and other outcomes [PASI 100, PASI 75, IGA 0, Dermatology Life Quality Index (DLQI) 0/1, absolute PASI, scalp IGA, Psoriasis Symptoms and Impacts Measure (P-SIM) responses]. Safety analyses were conducted.

Results

There were 108 Japanese randomized patients (bimekizumab: 62; ustekinumab: 29; placebo: 17). At week 16, bimekizumab-treated patients had a higher clinical response versus ustekinumab and placebo (PASI 90: 85.5% versus 51.7% and 5.9%; IGA 0/1: 82.3% versus 48.3% and 0.0%). Over 52 weeks, improved clinical response was maintained with bimekizumab, including patients switching from placebo at week 16. Overall, the safety profile in Japanese patients was consistent with that observed in the global population.

Conclusion

Bimekizumab resulted in improved clinical response versus ustekinumab and placebo, and was well-tolerated in Japanese patients.

Trial registration

NCT03370133.

Graphical Abstract

Hinweise

Supplementary Information

The online version contains supplementary material available at https://​doi.​org/​10.​1007/​s13555-022-00883-y.
Key Summary Points
Why carry out this study?
Biologic treatments targeting the IL-17 pathway have been recommended for treating patients with psoriasis, specifically in those who have not adequately responded to standard systematic therapies
Bimekizumab (BKZ) treatment, which inhibits IL-17A and IL-17F, has showed clinically meaningful improvements in patients with moderate-to-severe plaque psoriasis in BE VIVID, a global, 52-week, phase 3, randomized, ustekinumab and placebo-controlled study
This study aimed to evaluate the efficacy and safety of BKZ in the BE VIVID Japan patient subpopulation
What was learned from the study?
BKZ treatment resulted in improved clinical response compared with ustekinumab and placebo, and was well-tolerated in Japanese patients
These findings support the use of BKZ as a viable treatment option for Japanese patients with moderate-to-severe plaque psoriasis

Digital Features

This article is published with digital features, including a graphical abstract, to facilitate understanding of the article. To view digital features for this article go to https://​doi.​org/​10.​6084/​m9.​figshare.​21762908.

Introduction

Plaque psoriasis is a chronic, immune-mediated, inflammatory disease characterized by prominent skin lesions, which can be scaly, thick, and occasionally pruritic [1], and a substantial disease burden impacting on patient quality of life (QoL) [2, 3]. Psoriasis is additionally associated with increased risk of several comorbidities [4].
Interleukin (IL)-17A and IL-17F play a central role in the pathogenesis of psoriasis and psoriatic arthritis [57], and both are overexpressed in psoriatic lesional skin [5, 7, 8]. IL-17A and IL-17F share ~50% structural similarity and form homo- and heterodimers, with overlapping proinflammatory functions [911]. Biologic therapy, including treatments targeting the IL-17 pathway, are recommended by the Japanese Dermatological Association for patients with plaque-type psoriasis who have not adequately responded to standard systemic therapies and have ≥ 10% body surface area (BSA) affected, or who have refractory skin or joint symptoms intractable to systemic therapies and significantly impaired QoL [12].
Common biologic therapies targeting the IL-17 pathway inhibit IL-17 or target the IL-17 receptor complex [1316]. Anti-IL-17A agents have demonstrated efficacy in treating patients with moderate-to-severe psoriasis; however, nearly one-third of patients have discontinued treatment within 5 years due to ineffectiveness, primary or secondary failure, infection, or other causes, and require additional treatment options [17]. Additionally, other factors may affect patient preferences when choosing biologic therapy and patients may prioritize different factors. A survey of 395 Japanese patients with psoriasis reported patients preferred drugs with long-term and early-onset efficacy, sustained efficacy after drug withdrawal, and low risk of serious infection, among other factors [18].
Bimekizumab is a humanized monoclonal immunoglobulin G1 antibody that selectively binds with high affinity to IL-17A and IL-17F, inhibiting downstream signaling [19, 20]. In four phase 3/3b clinical trials, bimekizumab demonstrated clinical superiority over placebo, adalimumab, secukinumab, and ustekinumab in patients with moderate-to-severe plaque psoriasis [2124]. Recently, bimekizumab was approved in Japan for the treatment of plaque psoriasis, generalized pustular psoriasis, and psoriatic erythroderma in patients who are not sufficiently responding to existing treatments [25].
Prevalence and severity of psoriasis can significantly vary between populations and countries due to genetic and environmental factors [2628]. A lower prevalence of psoriasis in all ages was reported in Japan (0.4%), compared with Europe (0.7–2.9%) and the USA (5.1%) [26]. Additionally, psoriasis occurs predominantly in males in Japan [29, 30], unlike the approximately equal distribution of males and females in Western countries [28]. Higher expression of IL-17A and IL-17-regulated proinflammatory cytokines has been shown in Asian versus Western patients with plaque psoriasis [27]. Asian patients also tend to have milder forms of psoriasis, characterized by lesions of less epidermal thickness and radial expansion, compared with Western patients [27].
Absolute Psoriasis Area and Severity Index (PASI) thresholds represent relevant treatment targets in psoriasis and can supplement percentage PASI improvement when assessing treatment efficacy [31]. Among Japanese patients with plaque psoriasis, absolute PASI values of ≤ 2 or ≤ 3 have been used to demonstrate the efficacy of biologics [32, 33]. Absolute PASI values have also been shown to correlate with better QoL [or low Dermatology Life Quality Index (DLQI) values] [34].
Given the differences in disease epidemiology and severity between Japanese versus Western patient populations, this analysis of the BE VIVID Japan patient subpopulation aimed to evaluate the efficacy of bimekizumab in these patients. Absolute PASI values are reported alongside percentage PASI improvement, and other efficacy and safety outcomes.

Methods

Study Design

BE VIVID (NCT03370133) was a phase 3, randomized, double-blinded, ustekinumab and placebo-controlled, multicenter study of bimekizumab in patients with moderate-to-severe plaque psoriasis. The study design was published previously [24]. The reported analysis was prespecified in the protocol and includes patients enrolled in BE VIVID, recruited from 30 sites in Japan between February 2018 and December 2019. Eligible patients were randomized to receive bimekizumab 320 mg every 4 weeks (Q4W), ustekinumab (45 mg for patients ≤ 100 kg or 90 mg for patients > 100 kg) at weeks 0, 4, and every 12 weeks (Q12W), or placebo Q4W to week 16 followed by bimekizumab 320 mg Q4W to week 52 (Supplementary Fig. S2).
After completion of BE VIVID, eligible patients could enroll in BE BRIGHT (NCT03598790), a 144-week, open-label extension study assessing the long-term safety, tolerability, and efficacy of bimekizumab. Those not enrolled in BE BRIGHT had a safety follow-up visit 20 weeks after the last dose of study treatment.
All participants provided written informed consent. All results presented in this article are in aggregate form, and no personally identifiable information was used in this study. The study protocol, amendments, and patient-informed consent were reviewed by a national, regional, or independent ethics committee or institutional review board. This study was conducted in accordance with the current version of the applicable regulatory and International Conference on Harmonization–Good Clinical Practice requirements, ethical principles that have their origin in the principles of the Declaration of Helsinki, and local laws of countries involved.

Patients

Adults aged ≥ 18 years with moderate-to-severe plaque psoriasis [PASI ≥ 12, ≥ 10% BSA affected by psoriasis and Investigator’s Global Assessment (IGA) score ≥ 3 on a 5-point scale] for ≥ 6 months before screening were enrolled. Patients were included if they were eligible for systemic psoriasis therapy and/or phototherapy. Patients were excluded if they previously received bimekizumab and/or ustekinumab; had not responded within the first 12 weeks to any anti-IL-17 biologic or to > 1 non-anti-IL-17 biologic treatment; had a current or history of opportunistic, recurrent, or chronic infection. Full details of inclusion and exclusion criteria have been published previously [24].

Study Procedures

Efficacy and safety assessments were made at baseline, weeks 1, 2, 4, and Q4W thereafter through week 52. Data from the Psoriasis Symptoms and Impacts Measure (P-SIM), a 14-item patient-reported outcome (PRO) measure assessing severity of key signs, symptoms, and effects of psoriasis, where items, including pain, itch, and scaling, were scored daily (0–10; no–very severe) using a handheld electronic device [35], and averaged weekly through week 16. DLQI was measured at baseline, weeks 1, 2, 4, Q4W to week 16, and then Q12W thereafter through week 52.

Efficacy Outcomes

Efficacy endpoints in this analysis include the proportion of patients with an improvement of ≥ 90% from baseline in PASI (PASI 90) and IGA response score of 0 (clear skin) or 1 (almost clear skin) with ≥ 2 category improvement relative to baseline), both at week 16. Other endpoints in this analysis include the proportion of patients with PASI 100 (complete skin clearance) at week 16; IGA 0 response at week 16; PASI 75 at week 4; scalp IGA 0/1 response at week 16 in patients with scalp psoriasis at baseline; PASI 90 and IGA responses at weeks 12 and 52; P-SIM responses for itch (> 2.39), scaling (> 2.86), and pain (> 1.98) at week 16. P-SIM response thresholds were previously determined to represent a meaningful improvement in phase 3 study protocols of bimekizumab in psoriasis [36]. The proportion of patients with DLQI 0/1 (i.e., no effect of psoriasis on patient’s life), PASI 100, PASI 75, IGA 0, and absolute PASI ≤ 1, PASI ≤ 2, and PASI ≤ 3 responses through week 52 were also included.

Safety Outcomes

The occurrence of treatment emergent adverse events (TEAEs) and serious TEAEs was evaluated over 52 weeks of treatment, including common TEAEs, and safety topics of interest, including infections (serious, opportunistic, fungal, and tuberculosis), liver function test changes or enzyme elevations, inflammatory bowel disease, major cardiovascular adverse events, malignancies, anaphylactic reactions, neutropenia, and suicidal ideation and behavior. Suicidal ideation and behavior events, and major cardiovascular adverse events were adjudicated by an independent committee.

Statistical Analysis

Full details of statistical analyses performed have been previously reported [24]. Efficacy analyses included all randomized patients in the intention-to-treat (ITT) population. Clinical responses of treatment groups at specific timepoints were compared using the stratified Cochran-Mantel–Haenszel test. For binary variables, nonresponder imputation (NRI) was used to account for missing data. Observed case (OC) data were also reported. Given the small sample size of the Japan subpopulation, p-values were not reported.
Safety analyses of the initial treatment period included patients who had ≥ 1 dose of study treatment (safety set), while that of initial and maintenance treatment periods included patients who had ≥ 1 dose of active bimekizumab or ustekinumab (active medication set).

Results

Patients

Of the 735 patients screened in the overall population, 122 were from Japan. Of these, 108 were included in the ITT population: 62 patients received bimekizumab, 29 received ustekinumab, and 17 received placebo. For the initial and maintenance periods, the number of patients who discontinued the study was similar between treatment arms, considering the imbalance in size due to the randomization ratio (Fig. 1).
Demographics and baseline disease characteristics were balanced across treatment groups and were generally consistent with the BE VIVID global patient population, although some parameters were lower in the Japanese subpopulation, including mean weight, disease duration, DLQI, and prior biologic exposure (Table 1) [24]. Enrolled Japan subpopulation patients had a mean PASI of 22.3, mean BSA of 32.3, and 43/108 (39.8%) of patients had an IGA score of 4, indicating their psoriasis was severe. Most patients were male (89/108; 82.4%), and the mean age and weight across all patients were 51.6 years and 72.6 kg, respectively. Twenty-one (19.4%) patients had prior biologic exposure.
Table 1
Patient demographics and disease characteristics
Characteristica
Placebo
Bimekizumab 320 mg Q4W
Ustekinumabb
Overall
Japan (n = 17)
Global (N = 83)
Japan (n = 62)
Global (N = 321)
Japan (n = 29)
Global (N = 163)
Japan (n = 108)
Global (N = 567)
Age (years), mean ± SD
53.2 ± 13.3
49.7 ± 13.6
49.7 ± 12.4
45.2 ± 14.0
54.9 ± 13.8
46.0 ± 13.6
51.6 ± 13.0
46.1 ± 13.9
Weight (kg), mean ± SD
71.9 ± 13.4
89.1 ± 26.4
74.1 ± 18.3
88.7 ± 23.1
69.8 ± 15.8
87.2 ± 21.1
72.6 ± 16.9
88.4 ± 23.0
Male, n (%)
16 (94.1)
60 (72.3)
53 (85.5)
229 (71.3)
20 (69.0)
117 (71.8)
89 (82.4)
406 (71.6)
Duration of psoriasis (years), mean ± SD
10.4 ± 7.1
19.7 ± 13.8
12.0 ± 8.0
16.0 ± 11.6
15.6 ± 10.2
17.8 ± 11.6
12.7 ± 8.7
17.1 ± 12.0
PASI,
mean ± SD
20.5 ± 6.6
20.1 ± 6.8
23.1 ± 9.9
22.0 ± 8.6
21.5 ± 8.9
21.3 ± 8.3
22.3 ± 9.2
21.5 ± 8.3
BSA (%),
mean ± SD
30.3 ± 17.0
27.0 ± 16.3
33.5 ± 20.0
29.0 ± 17.1
30.9 ± 20.7
27.3 ± 16.7
32.3 ± 19.6
28.2 ± 16.9
IGA, n (%)c
 3: moderate
 4: severe
8 (47.1)
9 (52.9)
54 (65.1)
28 (33.7)
39 (62.9)
23 (37.1)
201 (62.6)
119 (37.1)
18 (62.1)
11 (37.9)
96 (58.9)
66 (40.5)
65 (60.2)
43 (39.8)
351 (61.9)
213 (37.6)
DLQI total,
mean ± SD
7.6 ± 6.0
10.0 ± 6.8
7.2 ± 4.7
9.9 ± 6.3
7.8 ± 5.4
11.0 ± 6.9
7.4 ± 5.1
10.2 ± 6.6
P-SIM score (mean ± SD), n
 Pain
 Itch
 Scaling
14
3.9 ± 3.2
5.6 ± 2.5
6.0 ± 2.5
67
5.1 ± 2.9
6.1 ± 2.5
6.6 ± 2.3
58
5.2 ± 2.8
6.1 ± 2.3
6.1 ± 2.4
260
5.7 ± 2.9
6.6 ± 2.4
6.7 ± 2.3
27
5.2 ± 3.5
6.4 ± 2.6
6.9 ± 2.5
124
5.7 ± 2.9
6.6 ± 2.4
6.8 ± 2.4
99
5.0 ± 3.0
6.1 ± 2.4
6.3 ± 2.4
451
5.6 ± 2.9
6.5 ± 2.4
6.7 ± 2.3
Prior systemic therapy, n (%)
14 (82.4)
64 (77.1)
55 (88.7)
267 (83.2)
24 (82.8)
132 (81.0)
93 (86.1)
463 (81.7)
Prior biologic therapy, n (%)d
 Anti-TNF
 Anti-IL-17
 Anti-IL-23
3 (17.6)
2 (11.8)
1 (5.9)
0
33 (39.8)
16 (19.3)
18 (21.7)
5 (6.0)
14 (22.6)
2 (3.2)
9 (14.5)
4 (6.5)
125 (38.9)
51 (15.9)
76 (23.7)
16 (5.0)
4 (13.8)
2 (6.9)
1 (3.4)
1 (3.4)
63 (38.7)
24 (14.7)
38 (23.3)
6 (3.7)
21 (19.4)
6 (5.6)
11 (10.2)
5 (4.6)
221 (39.0)
91 (16.0)
132 (23.3)
27 (4.8)
BSA body surface area, DLQI Dermatology Life Quality Index, IGA Investigator’s Global Assessment, IL interleukin, PASI Psoriasis Area Severity Index, PRO patient-reported outcome, P-SIM Psoriasis Symptoms and Impacts Measure, a 14-item PRO measure assessing severity of key signs, symptoms, and effects of psoriasis, where items were scored daily (0–10, no–very severe) using a handheld electronic device and averaged weekly through week 16, Q4W every 4 weeks, SD standard deviation, TNF tumor necrosis factor
aRandomized set
bPatients received ustekinumab at baseline and week 4, then every 12 weeks thereafter; ustekinumab dosing was based on weight: patients ≤100 kg at baseline received one ustekinumab 45 mg injection and one placebo injection, patients >100 kg at baseline received two ustekinumab 45 mg injections
cIn each treatment group of the global study population, one patient with mild IGA score was mistakenly enrolled
dIncludes patients with multiple prior biologic use

Clinical Efficacy Endpoints (NRI)

More patients receiving bimekizumab than those receiving ustekinumab and placebo achieved PASI 90 and an IGA score of 0/1 at week 16. PASI 90 was achieved by 85.5% bimekizumab- versus 51.7% ustekinumab- and 5.9% placebo-treated patients (Fig. 2a). IGA 0/1 was achieved by 82.3% bimekizumab- versus 48.3% ustekinumab- and 0% placebo-treated patients (Fig. 2b).
Complete skin clearance (PASI 100) was achieved by more patients receiving bimekizumab at week 16 versus ustekinumab and placebo (51.6% versus 13.8% and 0%, respectively; Fig. 2c). More patients receiving bimekizumab achieved IGA 0 at week 16 versus ustekinumab and placebo (51.6% versus 17.2% and 0%, respectively; Fig. 2d).
Higher responses were observed with bimekizumab treatment versus ustekinumab and placebo as early as week 4, after one bimekizumab dose. At week 4, PASI 75 was achieved by 85.5% bimekizumab- versus 3.4% ustekinumab- and 0% placebo-treated patients (Supplementary Fig. S1a). Higher response rates at week 4 were also observed for PASI 90 and IGA 0/1 (Supplementary Fig. S1b and S1c).
The higher proportion of bimekizumab-treated patients achieving PASI 90 and IGA 0/1 versus ustekinumab were maintained through week 52. At week 52, PASI 90 was achieved by 80.6% bimekizumab- versus 48.3% ustekinumab-treated patients (Fig. 3a). IGA 0/1 was achieved by 74.2% bimekizumab- versus 44.8% ustekinumab-treated patients (Fig. 3b). PASI 100, IGA 0, and PASI 75 response rates were also maintained through week 52 in bimekizumab-treated patients (Fig. 3c–e). By week 52, patients who switched from placebo to bimekizumab at week 16 showed similar responses in all efficacy outcomes to patients initially randomized to receive bimekizumab (Fig. 3).
At week 16, more bimekizumab-treated patients achieved absolute PASI thresholds than ustekinumab- and placebo-treated patients. PASI ≤ 1 was achieved by 72.6% bimekizumab- versus 31.0% ustekinumab- and 0% placebo-treated patients (Fig. 3g). PASI ≤ 2 was achieved by 87.1% bimekizumab- versus 55.2% ustekinumab- and 0% placebo-treated patients (Fig. 3h). PASI ≤ 3 was achieved by 93.5% bimekizumab- versus 65.5% ustekinumab- and 5.9% placebo-treated patients (Fig. 3i).
A fast onset of clinical (absolute PASI) response was also observed with bimekizumab. After one bimekizumab dose at week 4, more bimekizumab patients achieved PASI ≤ 2 (50.0%) versus ustekinumab (3.4%) and placebo (0%) (Fig. 3h).
At week 52, absolute PASI responses were maintained or improved, with more bimekizumab- versus ustekinumab-treated patients achieving absolute PASI thresholds. PASI ≤ 1 was achieved by 74.2% versus 31.0% (Fig. 3g), PASI ≤ 2 by 80.6% versus 48.3% (Fig. 3h), and PASI ≤ 3 by 82.3% versus 58.6% (Fig. 3i) of bimekizumab- versus ustekinumab-treated patients, respectively.

Patient-Reported Outcomes (PROs)

Bimekizumab-treated patients experienced greater benefits in terms of QoL than ustekinumab- and placebo-treated patients. At week 16, a greater proportion of bimekizumab-treated patients reported DLQI 0/1 (i.e., no effect of psoriasis on patient’s life) versus ustekinumab- and placebo-treated patients (66.1% versus 31.0% and 11.8%, respectively; Fig. 2e). A higher DLQI 0/1 response among bimekizumab-treated patients was observed as early as week 4 (Supplementary Fig. S1d), and maintained through week 52 (Fig. 3f).
At week 16, a higher proportion of bimekizumab-treated patients achieved P-SIM responses versus placebo-treated patients. A higher proportion of bimekizumab-treated patients achieved P-SIM responses based on pain item score improvement thresholds versus ustekinumab-treated patients (Supplementary Table S1).

Safety

The frequency of TEAEs was overall similar across all treatment groups during the initial 16-week treatment period (Table 2). Through weeks 0–16, TEAEs occurred in 40/62 (64.5%) bimekizumab-, 17/29 (58.6%) ustekinumab-, and 7/17 (41.2%) placebo-treated patients. Serious TEAEs were reported in 1/62 (1.6%) bimekizumab-, 1/29 (3.4%) ustekinumab-, and 0/17 placebo-treated patients.
Table 2
Overview of adverse events
Safety eventa
Initial period (weeks 0–16)
Initial and maintenance periods (weeks 0–52)
Placebo (n = 17)
n (%)
Bimekizumab 320 mg Q4W (n = 62)
n (%)
Ustekinumab (n = 29)
n (%)
Bimekizumab 320 mg Q4Wb (n = 77)
n (%)
Ustekinumab (n = 29)
n (%)
Summary of TEAEs
 Any TEAE
7 (41.2)
40 (64.5)
17 (58.6)
65 (84.4)
23 (79.3)
 Serious TEAEs
0
1 (1.6)
1 (3.4)
5 (6.5)
2 (6.9)
 Discontinuation due to TEAEs
1 (5.9)
1 (1.6)
1 (3.4)
6 (7.8)
2 (6.9)
 Treatment-related TEAEs
1 (5.9)
19 (30.6)
5 (17.2)
33 (42.9)
8 (27.6)
 Severe TEAEs
0
0
1 (3.4)
2 (2.6)
1 (3.4)
 Deaths
0
0
0
0
0
Common TEAEs
 Nasopharyngitis
1 (5.9)
8 (12.9)
2 (6.9)
20 (26.0)
7 (24.1)
 Oral candidiasis
0
6 (9.7)
0
13 (16.9)
0
 Eczema
0
2 (3.2)
1 (3.4)
9 (11.7)
1 (3.4)
 Folliculitis
0
2 (3.2)
0
7 (9.1)
0
 Contact dermatitis
0
2 (3.2)
0
6 (7.8)
1 (3.4)
 Pharyngitis
0
3 (4.8)
0
6 (7.8)
2 (6.9)
 Tinea pedis
0
3 (4.8)
0
6 (7.8)
1 (3.4)
TEAEs of interestc
 Fungal infections
0
11 (17.7)
0
23 (29.9)
1 (3.4)
  Candida
0
7 (11.3)
0
16 (20.8)d
0
  Tinea
0
4 (6.5)
0
8 (10.4)
1 (3.4)
Hepatic events
0
2 (3.2)
0
4 (5.2)
0
 Elevated liver enzymese
0
2 (3.2)
0
2 (2.6)
0
Adjudicated suicidal ideation and behavior
0
0
0
1 (1.3)
0
Q4W every 4 weeks, TEAE treatment emergent adverse event
aData for the initial period are from patients in the safety set, and data for initial and maintenance periods are from patients in the active medication set
bIncludes patients switching from placebo to bimekizumab 320 mg Q4W at week 16, where only events occurring after switching are included in this column
cThere were zero cases of other safety topics of interest (not presented in table), including systematic opportunistic infections, interstitial lung disease, active tuberculosis, inflammatory bowel disease, adjudicated major cardiovascular adverse events, malignancies, anaphylactic reactions, or neutropenia events
dIn bimekizumab-treated patients, there were 13 cases of oral candidiasis, three cases of esophageal candidiasis, and one case of oropharyngeal candidiasis (numbers are not additive)
eElevated liver enzymes/liver function tests included the following preferred terms reported as adverse events: hepatic enzyme increased and gamma-glutamyltransferase increased
Throughout the study (weeks 0–52), 65/77 (84.4%) patients receiving ≥ 1 bimekizumab dose (including patients who switched from placebo at week 16) and 23/29 (79.3%) patients receiving ≥ 1 ustekinumab dose reported TEAEs. Serious TEAEs occurred in 5/77 (6.5%) bimekizumab- and 2/29 (6.9%) ustekinumab-treated patients. Treatment-related TEAEs occurred in 33/77 (42.9%) patients receiving ≥ 1 bimekizumab dose and 8/29 (27.6%) patients receiving ≥ 1 ustekinumab dose. Discontinuations due to TEAEs were reported in 6/77 (7.8%) bimekizumab- and 2/29 (6.9%) ustekinumab-treated patients. No deaths were reported.
Common TEAEs in bimekizumab-treated patients throughout the study were nasopharyngitis, oral candidiasis, and eczema. Up to and including week 52, Candida and Tinea infections were reported in 16/77 (20.8%) and 8/77 (10.4%) bimekizumab-treated, and 0/29 and 1/29 (3.4%) ustekinumab-treated patients. The most common Candida and Tinea infections included oral candidiasis and Tinea pedis. Of the 13 bimekizumab-treated patients who reported oral candidiasis in weeks 0–52, none were serious or severe (ten were mild and three were moderate) and two led to discontinuation (these cases were recurrent). All bimekizumab-treated patients who reported Tinea pedis were mild cases and none led to discontinuation. There were 3/77 (3.9%) esophageal Candida infections among bimekizumab-treated and none among ustekinumab-treated patients. Of the three cases, two were mild, while one (1.3%) was serious, severe, and led to discontinuation (patient was hospitalized, received antifungal therapy, and the infection resolved in 14 days). There was a higher number of reported cases of candidiasis in weeks 0–16 (7/62; 11.3%) than weeks 16–52 (4/60; 6.7%); the number of cases with candidiasis were not additive. There were no other serious infections in bimekizumab-treated patients. All opportunistic infections were localized mucocutaneous fungal infections and were defined as opportunistic by convention.
Among other safety topics of interest, 2/77 (2.6%) bimekizumab-treated patients reported an elevated liver enzymes event. Both patients had confounding factors and alternative explanations (alcohol consumption) for these abnormalities. There was 1/77 (1.3%) case of adjudicated suicidal ideation and behavior (referring to active suicidal ideation with some intent to act in a patient with pre-existing psychiatric conditions) in the bimekizumab arm, and none with ustekinumab. Across all treatment groups, there were no cases of inflammatory bowel disease, adjudicated major cardiovascular adverse events, malignancies, anaphylactic reactions, or neutropenia events.

Discussion

In this phase 3 active comparator and placebo-controlled trial, bimekizumab demonstrated improved efficacy compared with ustekinumab and placebo for the treatment of adult patients with moderate-to-severe plaque psoriasis. Overall, the Japan patient subpopulation results were generally consistent with the global study population [24]. These findings suggest bimekizumab may be a viable treatment option in Japan, and effectiveness of bimekizumab treatment and dosing regimens in Japanese patients may be approximated from observations in Western populations.
Bimekizumab showed a faster onset of clinical response among Japanese patients compared with ustekinumab. The rapid onset was comparable between patients who received bimekizumab from week 0 and those who switched from placebo to bimekizumab at week 16. A fast onset of effectiveness is relevant as the Japanese Dermatological Association views this as an important consideration when selecting biologic therapy for psoriatic patients in Japan [12]. Japanese patients with psoriasis have also shown a preference for drugs with early-onset efficacy [18].
Patients with chronic plaque psoriasis can lose treatment response over time [12, 37], and may need to switch treatments to maintain high skin clearance levels [12]. In this analysis, high proportions of bimekizumab-treated patients maintained good skin clearance through 52 weeks of treatment.
Additionally, more bimekizumab-treated patients reached absolute PASI thresholds versus ustekinumab or placebo. Absolute PASI has been used as an efficacy measure in Japanese clinics, as evidenced in a number of studies assessing absolute PASI responses in Japanese patients with moderate-to-severe psoriasis [3234].
As psoriasis often has a detrimental impact on patient QoL [2], it is important that clinical improvements in skin clearance can be linked to QoL improvements. A correlation between absolute PASI and DLQI has been shown in a study of Japanese patients with moderate-to-severe plaque psoriasis: in those who experienced a relapse, a change in absolute PASI response correlated with a steeper increase in DLQI scores compared with baseline [34]. As this analysis measured relative and absolute PASI responses, DLQI, PROs, and other clinical outcomes, it provides holistic insight—across clinical and QoL outcomes—of the clinical benefits of bimekizumab in Japanese patients with psoriasis.
Overall, safety results for Japanese patients were consistent with the BE VIVID global study population [24], with a slightly higher incidence of TEAEs related to skin and subcutaneous disorders, in particular eczema and contact dermatitis. Over 52 weeks, the occurrence of common TEAEs was comparable between bimekizumab and ustekinumab, except for oral candidiasis. As the IL-17 pathway controls fungal infections of the oral mucosa, and is subject to heightened inhibition through bimekizumab’s inhibition of IL-17F and IL-17A [3842], oral candidiasis would be expected to be more common in bimekizumab- versus ustekinumab-treated patients. Moreover, the frequency of oral candiasis infections was similar to observations in previous bimekizumab trials [19, 24, 43, 44], and was higher than observations with other IL-17 inhibitors [13, 14]. This might result from bimekizumab’s inhibition of IL-17F and IL-17A; further investigations can confirm this. Finally, while there was a higher number of reported candidiasis cases among Japanese patients in weeks 0–16 than in weeks 16–52, the results should be interpreted with caution given the small number of patients.

Limitations

Inferential comparisons of the outcomes and calculation of p-values were not prespecified given the small patient numbers in this analysis. Therefore, p-values have not been reported as the interpretation of those results may be limited. Absolute numbers and percentages have instead been reported for the various outcomes. Nonetheless, the current analysis provides evidence of bimekizumab efficacy and safety in Japanese patients, whereby clinical response is consistent with the overall population.
Head-to-head comparator trials are important for comparing between treatments; studies comparing bimekizumab with IL-17A or TNFα inhibitors have been published previously [22, 23]. These studies, together with the present analysis, contribute toward the wider program evaluating bimekizumab efficacy and safety in adults with moderate-to-severe plaque psoriasis.
Finally, long-term data on bimekizumab efficacy and safety will be available through the ongoing open-label extension study (BE BRIGHT), which has recruited patients from this analysis and others in the “bimekizumab for psoriasis” program. These data would allow patients and clinicians in Japan to make informed treatment decisions.

Conclusions

Consistent with results of the global study population, bimekizumab treatment led to improved clinical responses compared with ustekinumab and placebo in the Japan subpopulation. Clinically meaningful responses and benefits in PROs and QoL were rapid in onset and durable through 52 weeks, providing evidence that bimekizumab could offer an additional treatment option for Japanese patients with moderate-to-severe plaque psoriasis. Bimekizumab was well-tolerated and the safety profile in this analysis was consistent with the known mechanism of action and previous studies.

Acknowledgements

Funding

This study was sponsored by UCB Pharma. This article was based on the original study (BE VIVID [NCT03370133]) sponsored by UCB Pharma. Support for third party writing assistance for this article, provided by Sharon Lee, PhD, Costello Medical, Singapore, and Emma Phillips, PhD, Costello Medical, UK, was funded by UCB Pharma in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3). The Rapid Service Fee will be funded by UCB Pharma.

Medical Writing, Editorial, and Other Assistance

The authors thank the patients, the investigators, and their teams who took part in this study. The authors acknowledge Bartosz Lukowski, PhD, Sadayoshi Onodera, PhD, and Kazuteru Wada, PhD from UCB Pharma, Japan, for publication coordination and Sharon Lee, PhD from Costello Medical, Singapore, and Emma Phillips, PhD, from Costello Medical, UK, for medical writing and editorial assistance based on the authors’ input and direction.

Authorship

All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Author Contributions

Conceptualization: Maggie Wang; Data Curation: Maggie Wang; Formal analysis: Akihiko Asahina, Yukari Okubo, Akimichi Morita, Yayoi Tada, Atsuyuki Igarashi, Richard G. Langley, Delphine Deherder, Mizuho Matano, Veerle Vanvoorden, Maggie Wang, Mamitaro Ohtsuki, Hidemi Nakagawa; Funding Acquisition: Delphine Deherder, Mizuho Matano, Veerle Vanvoorden, Maggie Wang; Investigation: Delphine Deherder, Mizuho Matano, Veerle Vanvoorden, Maggie Wang; Methodology: Maggie Wang; Resources: Delphine Deherder, Mizuho Matano, Veerle Vanvoorden, Maggie Wang; Supervision: Veerle Vanvoorden; Validation: Delphine Deherder, Maggie Wang; Visualization: Akihiko Asahina, Yukari Okubo, Akimichi Morita, Yayoi Tada, Atsuyuki Igarashi, Richard G. Langley, Delphine Deherder, Mizuho Matano, Veerle Vanvoorden, Maggie Wang, Mamitaro Ohtsuki, Hidemi Nakagawa; Writing – Original Draft Preparation: Akihiko Asahina, Yukari Okubo, Akimichi Morita, Yayoi Tada, Atsuyuki Igarashi, Richard G. Langley, Delphine Deherder, Mizuho Matano, Veerle Vanvoorden, Maggie Wang, Mamitaro Ohtsuki, Hidemi Nakagawa; Writing – Review and Editing: Akihiko Asahina, Yukari Okubo, Akimichi Morita, Yayoi Tada, Atsuyuki Igarashi, Richard G. Langley, Delphine Deherder, Mizuho Matano, Veerle Vanvoorden, Maggie Wang, Mamitaro Ohtsuki, Hidemi Nakagawa.

Disclosures

Akihiko Asahina: Honoraria and/or research grants from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eisai, Eli Lilly, Janssen, Kyowa Kirin, LEO Pharma, Maruho, Mitsubishi Tanabe Pharma, Novartis, Pfizer, Sun Pharma, Taiho Pharmaceutical, Torii Pharmaceutical, and UCB Pharma. Yukari Okubo: Research grants from Eisai, Maruho, Shiseido, and Torii Pharmaceutical; current consulting/advisory board agreements from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Janssen, and Sun Pharma; speakers bureau from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eisai, Eli Lilly, Janssen, Jimro, Kyowa Kirin, LEO Pharma, Maruho, Mitsubishi Tanabe Pharma, Novartis, Pfizer, Sanofi, Sun Pharma, Taiho Pharmaceutical, Torii Pharmaceutical, and UCB Pharma; clinical trials sponsored by AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, LEO Pharma, Maruho, Pfizer, Sun Pharma, and UCB Pharma. Akimichi Morita: Research grants, consulting fees, and/or speaker’s fees from AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eisai, Eli Lilly, Janssen, Kyowa Hakko Kirin, LEO Pharma, Maruho, Mitsubishi Tanabe Pharma, Nichi-Iko, Nippon Kayaku, Novartis, Pfizer, Sun Pharma, Taiho Pharmaceutical, Torii Pharmaceutical, Ushio, and UCB Pharma. Yayoi Tada: Honoraria and/or grants from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eisai, Eli Lilly, Janssen, Kyowa Kirin, LEO Pharma, Maruho, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, Novartis, Sun Pharma, Taiho Pharmaceutical, Torii Pharmaceutical, and UCB Pharma. Atsuyuki Igarashi: Speaker honoraria from AbbVie, Celgene, Eisai, Eli Lilly, Janssen Pharmaceutical, Kyowa Kirin, Maruho, Novartis, and Torii Pharmaceutical; research grants from Amgen, AbbVie, Bristol Myers Squibb, Eli Lilly, and LEO Pharma. Richard G. Langley: Principal investigator for AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, LEO Pharma, Merck, Novartis, Pfizer, and UCB Pharma; served on scientific advisory boards for AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, LEO Pharma, Merck, Novartis, Pfizer, and UCB Pharma; provided lectures for AbbVie, Amgen, Celgene, LEO Pharma, Merck, Novartis, and Pfizer. Delphine Deherder, Veerle Vanvoorden, Maggie Wang: Employees and shareholders of UCB Pharma. Mizuho Matano: Employee of UCB Pharma. Mamitaro Ohtsuki: Honoraria and/or research grants from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eisai, Eli Lilly, Janssen, Kyowa Kirin, LEO Pharma, Maruho, Mitsubishi Tanabe Pharma, Nichi-Iko, Nippon Kayaku, Novartis, Pfizer, Sun Pharma, Taiho Pharmaceutical, Torii Pharmaceutical, and UCB Pharma. Hidemi Nakagawa: Consulting fees, and/or speaker's fees from AbbVie, Janssen, Japan Tobacco Inc., Kyowa Hakko Kirin, LEO Pharma, Maruho, Taiho Pharmaceutical, Torii Pharmaceutical, and UCB Pharma.

Compliance With Ethics Guidelines

All participants provided written informed consent. All results presented in this article are in aggregate form, and no personally identifiable information was used in this study. The study protocol, amendments, and patient-informed consent were reviewed by a national, regional, or independent ethics committee or institutional review board. This study was conducted in accordance with the current version of the applicable regulatory and International Conference on Harmonisation–Good Clinical Practice requirements, ethical principles that have their origin in the principles of the Declaration of Helsinki, and local laws of countries involved.

Data Availability

Underlying data from this manuscript may be requested by qualified researchers 6 months after product approval in the USA and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Prior Presentation

This manuscript is based on work that has been previously presented at the Japanese Society for Psoriasis Research (3–4 September 2021) and International Congress of Dermatology (10–13 November 2021) congresses.
Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by-nc/​4.​0/​.
Anhänge

Supplementary Information

Below is the link to the electronic supplementary material.
Literatur
3.
Zurück zum Zitat Kimball AB, Jacobson C, Weiss S, Vreeland MG, Wu Y. The psychosocial burden of psoriasis. Am J Clin Dermatol. 2005;6(6):383–92.PubMedCrossRef Kimball AB, Jacobson C, Weiss S, Vreeland MG, Wu Y. The psychosocial burden of psoriasis. Am J Clin Dermatol. 2005;6(6):383–92.PubMedCrossRef
5.
Zurück zum Zitat Johansen C, Usher PA, Kjellerup RB, et al. Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. Br J Dermatol. 2009;160(2):319–24.PubMedCrossRef Johansen C, Usher PA, Kjellerup RB, et al. Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. Br J Dermatol. 2009;160(2):319–24.PubMedCrossRef
6.
Zurück zum Zitat van Baarsen LGM, Lebre MC, van der Coelen D, et al. Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy? Arthritis Res Ther. 2014;16(4):426.PubMedPubMedCentralCrossRef van Baarsen LGM, Lebre MC, van der Coelen D, et al. Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy? Arthritis Res Ther. 2014;16(4):426.PubMedPubMedCentralCrossRef
7.
Zurück zum Zitat Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018;55(3):379–90.PubMedPubMedCentralCrossRef Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018;55(3):379–90.PubMedPubMedCentralCrossRef
8.
Zurück zum Zitat Johnston A, Fritz Y, Dawes SM, et al. Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation. J Immunol. 2013;190(5):2252–62.PubMedCrossRef Johnston A, Fritz Y, Dawes SM, et al. Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation. J Immunol. 2013;190(5):2252–62.PubMedCrossRef
9.
Zurück zum Zitat Chang SH, Dong C. A novel heterodimeric cytokine consisting of IL-17 and IL-17F regulates inflammatory responses. Cell Res. 2007;17(5):435–40.PubMedCrossRef Chang SH, Dong C. A novel heterodimeric cytokine consisting of IL-17 and IL-17F regulates inflammatory responses. Cell Res. 2007;17(5):435–40.PubMedCrossRef
10.
Zurück zum Zitat Wright JF, Bennett F, Li B, et al. The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-17RA/IL-17RC receptor complex. J Immunol. 2008;181(4):2799–805.PubMedCrossRef Wright JF, Bennett F, Li B, et al. The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-17RA/IL-17RC receptor complex. J Immunol. 2008;181(4):2799–805.PubMedCrossRef
11.
Zurück zum Zitat Wright JF, Guo Y, Quazi A, et al. Identification of an interleukin 17F/17A heterodimer in activated human CD4+ T cells. J Biol Chem. 2007;282(18):13447–55.PubMedCrossRef Wright JF, Guo Y, Quazi A, et al. Identification of an interleukin 17F/17A heterodimer in activated human CD4+ T cells. J Biol Chem. 2007;282(18):13447–55.PubMedCrossRef
12.
Zurück zum Zitat Saeki H, Terui T, Morita A, et al. Japanese guidance for use of biologics for psoriasis (the 2019 version). J Dermatol. 2020;47(3):201–22.PubMedCrossRef Saeki H, Terui T, Morita A, et al. Japanese guidance for use of biologics for psoriasis (the 2019 version). J Dermatol. 2020;47(3):201–22.PubMedCrossRef
13.
Zurück zum Zitat Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541–51.PubMedCrossRef Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541–51.PubMedCrossRef
14.
Zurück zum Zitat Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med. 2014;371(4):326–38.PubMedCrossRef Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med. 2014;371(4):326–38.PubMedCrossRef
15.
Zurück zum Zitat Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318–28.PubMedCrossRef Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318–28.PubMedCrossRef
16.
Zurück zum Zitat Thaçi D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73(3):400–9.PubMedCrossRef Thaçi D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73(3):400–9.PubMedCrossRef
17.
Zurück zum Zitat Torres T, Puig L, Vender R, et al. Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for psoriasis treatment: a retrospective multi-country, multicentric cohort study. Am J Clin Dermatol. 2021;22(4):567–79.PubMedCrossRef Torres T, Puig L, Vender R, et al. Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for psoriasis treatment: a retrospective multi-country, multicentric cohort study. Am J Clin Dermatol. 2021;22(4):567–79.PubMedCrossRef
18.
Zurück zum Zitat Tada Y, Ishii K, Kimura J, Hanada K, Kawaguchi I. Patient preference for biologic treatments of psoriasis in Japan. J Dermatol. 2019;46(6):466–77.PubMedPubMedCentralCrossRef Tada Y, Ishii K, Kimura J, Hanada K, Kawaguchi I. Patient preference for biologic treatments of psoriasis in Japan. J Dermatol. 2019;46(6):466–77.PubMedPubMedCentralCrossRef
19.
Zurück zum Zitat Glatt S, Baeten D, Baker T, et al. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis. 2018;77(4):523–32.PubMedCrossRef Glatt S, Baeten D, Baker T, et al. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis. 2018;77(4):523–32.PubMedCrossRef
20.
Zurück zum Zitat Glatt S, Helmer E, Haier B, et al. First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis. Br J Clin Pharmacol. 2017;83(5):991–1001.PubMedPubMedCentralCrossRef Glatt S, Helmer E, Haier B, et al. First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis. Br J Clin Pharmacol. 2017;83(5):991–1001.PubMedPubMedCentralCrossRef
21.
Zurück zum Zitat Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet. 2021;397(10273):475–86.PubMedCrossRef Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet. 2021;397(10273):475–86.PubMedCrossRef
22.
Zurück zum Zitat Reich K, Warren RB, Lebwohl M, et al. Bimekizumab versus secukinumab in plaque psoriasis. N Engl J Med. 2021;385(2):142–52.PubMedCrossRef Reich K, Warren RB, Lebwohl M, et al. Bimekizumab versus secukinumab in plaque psoriasis. N Engl J Med. 2021;385(2):142–52.PubMedCrossRef
23.
Zurück zum Zitat Warren RB, Blauvelt A, Bagel J, et al. Bimekizumab versus adalimumab in plaque psoriasis. N Engl J Med. 2021;385(2):130–41.PubMedCrossRef Warren RB, Blauvelt A, Bagel J, et al. Bimekizumab versus adalimumab in plaque psoriasis. N Engl J Med. 2021;385(2):130–41.PubMedCrossRef
24.
Zurück zum Zitat Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet. 2021;397(10273):487–98.PubMedCrossRef Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet. 2021;397(10273):487–98.PubMedCrossRef
26.
Zurück zum Zitat Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205–12.PubMedCrossRef Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205–12.PubMedCrossRef
27.
Zurück zum Zitat Kim J, Oh C-H, Jeon J, et al. Molecular phenotyping small (Asian) versus large (Western) plaque psoriasis shows common activation of IL-17 pathway genes but different regulatory gene sets. J Invest Dermatol. 2016;136(1):161–72.PubMedPubMedCentralCrossRef Kim J, Oh C-H, Jeon J, et al. Molecular phenotyping small (Asian) versus large (Western) plaque psoriasis shows common activation of IL-17 pathway genes but different regulatory gene sets. J Invest Dermatol. 2016;136(1):161–72.PubMedPubMedCentralCrossRef
28.
Zurück zum Zitat Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–85.PubMedCrossRef Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–85.PubMedCrossRef
29.
Zurück zum Zitat Kubota K, Kamijima Y, Sato T, et al. Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database. BMJ Open. 2015;5(1):e006450.PubMedPubMedCentralCrossRef Kubota K, Kamijima Y, Sato T, et al. Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database. BMJ Open. 2015;5(1):e006450.PubMedPubMedCentralCrossRef
30.
Zurück zum Zitat Ogawa E, Okuyama R, Seki T, et al. Epidemiological survey of patients with psoriasis in Matsumoto city, Nagano Prefecture, Japan. J Dermatol. 2018;45(3):314–7.PubMedCrossRef Ogawa E, Okuyama R, Seki T, et al. Epidemiological survey of patients with psoriasis in Matsumoto city, Nagano Prefecture, Japan. J Dermatol. 2018;45(3):314–7.PubMedCrossRef
31.
Zurück zum Zitat Gordon KB, Reich K, Crowley JJ, et al. Disease activity and treatment efficacy using patient-level psoriasis area and severity index scores from tildrakizumab phase 3 clinical trials. J Dermatolog Treat. 2020;33:219–28.PubMedCrossRef Gordon KB, Reich K, Crowley JJ, et al. Disease activity and treatment efficacy using patient-level psoriasis area and severity index scores from tildrakizumab phase 3 clinical trials. J Dermatolog Treat. 2020;33:219–28.PubMedCrossRef
32.
Zurück zum Zitat Igarashi A, Nakagawa H, Morita A, et al. Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: results from a 64-week phase 3 study (reSURFACE 1). J Dematol. 2021;48(6):853–63. Igarashi A, Nakagawa H, Morita A, et al. Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: results from a 64-week phase 3 study (reSURFACE 1). J Dematol. 2021;48(6):853–63.
33.
Zurück zum Zitat Umezawa Y, Asahina A, Imafuku S, et al. Efficacy and safety of certolizumab pegol in Japanese patients with moderate to severe plaque psoriasis: 52-week results. Dermatol Ther. 2021;11(3):943–60.CrossRef Umezawa Y, Asahina A, Imafuku S, et al. Efficacy and safety of certolizumab pegol in Japanese patients with moderate to severe plaque psoriasis: 52-week results. Dermatol Ther. 2021;11(3):943–60.CrossRef
34.
Zurück zum Zitat Okubo Y, Ohtsuki M, Morita A, et al. Long-term efficacy and safety of secukinumab in Japanese patients with moderate to severe plaque psoriasis: 3-year results of a double-blind extension study. J Dermatol. 2019;46(3):186–92.PubMedPubMedCentralCrossRef Okubo Y, Ohtsuki M, Morita A, et al. Long-term efficacy and safety of secukinumab in Japanese patients with moderate to severe plaque psoriasis: 3-year results of a double-blind extension study. J Dermatol. 2019;46(3):186–92.PubMedPubMedCentralCrossRef
35.
Zurück zum Zitat Gottlieb AB, Ciaravino V, Cioffi C, Peterson L, Warren RB. Development and content validation of the Psoriasis Symptoms and Impacts Measure (P-SIM) for assessment of plaque psoriasis. Dermatol Ther. 2020;10(6):1255–72.CrossRef Gottlieb AB, Ciaravino V, Cioffi C, Peterson L, Warren RB. Development and content validation of the Psoriasis Symptoms and Impacts Measure (P-SIM) for assessment of plaque psoriasis. Dermatol Ther. 2020;10(6):1255–72.CrossRef
36.
Zurück zum Zitat Warren RB, Gottlieb AB, Merola JF, et al. Psychometric validation of the Psoriasis Symptoms and Impacts Measure (P-SIM), a novel patient-reported outcome Instrument for patients with plaque psoriasis, using data from the BE VIVID and BE READY phase 3 Trials. Dermatol Ther. 2021;11(5):1551–69. Warren RB, Gottlieb AB, Merola JF, et al. Psychometric validation of the Psoriasis Symptoms and Impacts Measure (P-SIM), a novel patient-reported outcome Instrument for patients with plaque psoriasis, using data from the BE VIVID and BE READY phase 3 Trials. Dermatol Ther. 2021;11(5):1551–69.
37.
Zurück zum Zitat Okubo Y, Tsuruta D, Tang AC, et al. Analysis of treatment goal alignment between Japanese psoriasis patients and their paired treating physicians. J Eur Acad Dermatol Venereol. 2018;32(4):606–14.PubMedCrossRef Okubo Y, Tsuruta D, Tang AC, et al. Analysis of treatment goal alignment between Japanese psoriasis patients and their paired treating physicians. J Eur Acad Dermatol Venereol. 2018;32(4):606–14.PubMedCrossRef
38.
Zurück zum Zitat Armstrong AW, Bukhalo M, Blauvelt A. A clinician’s guide to the diagnosis and treatment of candidiasis in patients with psoriasis. Am J Clin Dermatol. 2016;17(4):329–36.PubMedPubMedCentralCrossRef Armstrong AW, Bukhalo M, Blauvelt A. A clinician’s guide to the diagnosis and treatment of candidiasis in patients with psoriasis. Am J Clin Dermatol. 2016;17(4):329–36.PubMedPubMedCentralCrossRef
39.
Zurück zum Zitat Blauvelt A, Lebwohl MG, Bissonnette R. IL-23/IL-17A dysfunction phenotypes inform possible clinical effects from anti-IL-17A therapies. J Invest Dermatol. 2015;135(8):1946–53.PubMedPubMedCentralCrossRef Blauvelt A, Lebwohl MG, Bissonnette R. IL-23/IL-17A dysfunction phenotypes inform possible clinical effects from anti-IL-17A therapies. J Invest Dermatol. 2015;135(8):1946–53.PubMedPubMedCentralCrossRef
40.
Zurück zum Zitat Conti HR, Gaffen SL. IL-17-mediated immunity to the opportunistic fungal pathogen Candida albicans. J Immunol. 2015;195(3):780–8.PubMedCrossRef Conti HR, Gaffen SL. IL-17-mediated immunity to the opportunistic fungal pathogen Candida albicans. J Immunol. 2015;195(3):780–8.PubMedCrossRef
41.
Zurück zum Zitat Hiruma J, Harada K, Hirayama M, et al. Blockade of the IL-17 signaling pathway increased susceptibility of psoriasis patients to superficial fungal infections. J Dermatol Sci. 2021;101(2):145–6.PubMedCrossRef Hiruma J, Harada K, Hirayama M, et al. Blockade of the IL-17 signaling pathway increased susceptibility of psoriasis patients to superficial fungal infections. J Dermatol Sci. 2021;101(2):145–6.PubMedCrossRef
42.
Zurück zum Zitat Puel A, Cypowyj S, Bustamante J, et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science. 2011;332(6025):65–8.PubMedPubMedCentralCrossRef Puel A, Cypowyj S, Bustamante J, et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science. 2011;332(6025):65–8.PubMedPubMedCentralCrossRef
43.
Zurück zum Zitat Blauvelt A, Papp KA, Merola JF, et al. Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study. J Am Acad Dermatol. 2020;83:1367–74.PubMedCrossRef Blauvelt A, Papp KA, Merola JF, et al. Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study. J Am Acad Dermatol. 2020;83:1367–74.PubMedCrossRef
44.
Zurück zum Zitat Papp KA, Merola JF, Gottlieb AB, et al. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. J Am Acad Dermatol. 2018;79(2):277-86.e10.PubMedCrossRef Papp KA, Merola JF, Gottlieb AB, et al. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. J Am Acad Dermatol. 2018;79(2):277-86.e10.PubMedCrossRef
Metadaten
Titel
Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study
verfasst von
Akihiko Asahina
Yukari Okubo
Akimichi Morita
Yayoi Tada
Atsuyuki Igarashi
Richard G. Langley
Delphine Deherder
Mizuho Matano
Veerle Vanvoorden
Maggie Wang
Mamitaro Ohtsuki
Hidemi Nakagawa
Publikationsdatum
17.01.2023
Verlag
Springer Healthcare
Erschienen in
Dermatology and Therapy / Ausgabe 3/2023
Print ISSN: 2193-8210
Elektronische ISSN: 2190-9172
DOI
https://doi.org/10.1007/s13555-022-00883-y

Weitere Artikel der Ausgabe 3/2023

Dermatology and Therapy 3/2023 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.